NCT00308048View on ClinicalTrials.gov

14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

PHASE3CompletedINTERVENTIONAL

Enrollment

435

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

September 30, 2006

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

Pegylated Interferon alfa 2b and ribavirin

Trial Locations (1)

0407

Ullevaal University Hospital, Oslo

Sponsors

Collaborators (1)

Schering-Plough

All Listed Sponsors

collaborator

Schering-Plough

INDUSTRY

lead

Ullevaal University Hospital

OTHER